Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Issue 3 (21st February 2019)

• Record Type: Journal Article
• Authors: Harel, Efrat; Shoji, Jun; Abraham, Vivek; Miller, Loan; Laszik, Zoltan; Thurison, Tine; King, Andrew; Olshen, Adam; Leung, Joey; Szabo, Gyula; Hann, Byron; Høyer‐Hansen, Gunilla; Craik, Charles S.; Vincenti, Flavio
• Is Part Of: Clinical transplantation. Volume 33:Issue 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-02-21
• Subjects: focal segmental glomerulosclerosis -- suPAR -- suPAR forms -- uPAR (I); Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.13487
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Background: We investigated circulating levels of individual soluble urokinase plasminogen activation receptor (suPAR) forms to determine if specific circulating fragments of suPAR (II‐III) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis (FSGS) and the risk of recurrence after transplantation. Materials and Methods: Serum levels of intact suPAR and its cleaved forms were measured with two assays, ELISA and TR‐FIA. Results: suPAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact suPAR (I‐II‐III) levels were noted to be elevated in glomerular diseases including FSGS. uPAR fragment (I) levels measured with the TR‐FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, suPAR(I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients. Conclusion: Our analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR‐FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.